Xia Lu, Chen Jingyun, Huang Min, Mei Jie, Lin Min
Center for Uterine Cancer Diagnosis and Therapy Research of Zhejiang Province, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Front Oncol. 2022 Jul 19;12:963617. doi: 10.3389/fonc.2022.963617. eCollection 2022.
Accumulated evidence has revealed that F-box protein, a subunit of SCF E3 ubiquitin ligase complexes, participates in carcinogenesis and tumor progression targeting its substrates for ubiquitination and degradation. F-box proteins could be regulated by cellular signaling pathways and noncoding RNAs in tumorigenesis. Long noncoding RNA (lncRNA), one type of noncoding RNAs, has been identified to modulate the expression of F-box proteins and contribute to oncogenesis. In this review, we summarize the role and mechanisms of multiple lncRNAs in regulating F-box proteins in tumorigenesis, including lncRNAs SLC7A11-AS1, MT1JP, TUG1, FER1L4, TTN-AS1, CASC2, MALAT1, TINCR, PCGEM1, linc01436, linc00494, GATA6-AS1, and ODIR1. Moreover, we discuss that targeting these lncRNAs could be helpful for treating cancer modulating F-box protein expression. We hope our review can stimulate the research on exploration of molecular insight into how F-box proteins are governed in carcinogenesis. Therefore, modulation of lncRNAs is a potential therapeutic strategy for cancer therapy regulation of F-box proteins.
越来越多的证据表明,F-box蛋白作为SCF E3泛素连接酶复合物的一个亚基,通过将其底物靶向泛素化和降解来参与肿瘤发生和肿瘤进展。在肿瘤发生过程中,F-box蛋白可受细胞信号通路和非编码RNA的调控。长链非编码RNA(lncRNA)作为非编码RNA的一种,已被证实可调节F-box蛋白的表达并促进肿瘤发生。在本综述中,我们总结了多种lncRNA在肿瘤发生过程中调控F-box蛋白的作用及机制,包括lncRNA SLC7A11-AS1、MT1JP、TUG1、FER1L4、TTN-AS1、CASC2、MALAT1、TINCR、PCGEM1、linc01436、linc00494、GATA6-AS1和ODIR1。此外,我们讨论了靶向这些lncRNA可能有助于通过调节F-box蛋白表达来治疗癌症。我们希望我们的综述能够激发对F-box蛋白在肿瘤发生过程中如何被调控的分子机制探索的研究。因此,调节lncRNA是一种通过调控F-box蛋白进行癌症治疗的潜在策略。